A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
Campone, M., Bachelot, T., Penault-Llorca, F., Pallis, A., Agrapart, V., Pierrat, M. J., Poirot, C., Dubois, F., Xuereb, L., Bossard, C. J., Guigal-Stephan, N., Lockhart, B., Andre, F.Journal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-018-03765-3
Date:
January, 2019
File:
PDF, 1.15 MB
2019